Per Svenningsson’s research group

Translational Neuropharmacology

(Link to our Karolinska Institute webpage)

About us:

We are a translational and multidisciplinary research group studying movement disorders, particularly Parkinson’s disease, and depression. We use cellular and animal models and analyze samples and biopsies from patients. Our goals are to understand the molecular mechanisms underlying disease states, and to identify novel biomarkers and medically relevant therapeutic targets. 

At the clinic, we do longitudinal studies on cohorts of patients with Parkinson’s disease and other movement disorders, assessing both motor and non-motor symptoms. We also perform clinical trials with novel pharmacological therapies.

Recent News:

A full-length article in the journal Nature (co-authored by Justyna Zareba-Paslawska and Per Svenningsson) demonstrates a key role for MAPT-AS1 in tauopathies, such as frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration.  (study funded by CBD Solutions). Read article here.